Synopsys is Fundamentally Immune to AI Disruption Fears, BofA Says

MT Newswires Live02-26

Synopsys (SNPS) is fundamentally immune to artificial intelligence disruption fears as its complex tools remain crucial to expensive design processes, BofA Securities said in a Wednesday research report.

The company's joint development of services with Ansys, expected to start rolling out in H1, could drive upside to fiscal 2027 and 2028 estimates, analysts wrote.

The company saw momentum in hardware in fiscal Q1, including a "marquee emulation" win versus Cadence Design Systems' (CDNS) ASIC-driven platform at an AI high-performance computing client, indicating that the gap between the hardware performance of the companies could be smaller than realized, according to the note.

The brokerage said it reiterated its buy rating on the stock and cut its price target to $515 per share from $560.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment